These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38621719)

  • 1. Rituximab or cyclosporine a for the treatment of membranous nephropathy: Economic evaluation of the MENTOR trial.
    Kadatz M; Klarenbach S; So H; Fervenza FC; Cattran DC; Barbour SJ
    Nephrol Dial Transplant; 2024 Apr; ():. PubMed ID: 38621719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy for progressive idiopathic membranous nephropathy: a cost-effectiveness analysis in China.
    Xu W; Zhang Z; Li D; Dai W; Pan C; Guo M; Zhao Y; Cui X
    BMC Health Serv Res; 2023 Apr; 23(1):361. PubMed ID: 37046255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
    Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
    Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris.
    Chen MKY; Vissapragada R; Bulamu N; Gupta M; Werth V; Sebaratnam DF
    JAMA Dermatol; 2022 Sep; 158(9):1013-1021. PubMed ID: 35895045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model.
    Hamilton P; Kanigicherla D; Venning M; Brenchley P; Meads D
    Nephrol Dial Transplant; 2018 Dec; 33(12):2145-2155. PubMed ID: 29617884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
    Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
    J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
    [No Abstract]   [Full Text] [Related]  

  • 8. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China.
    Zeng L; Chen H; Xiang H; Zeng M; Zhou M; Tan C; Liu H; Chen G
    Front Pharmacol; 2023; 14():1309930. PubMed ID: 38259264
    [No Abstract]   [Full Text] [Related]  

  • 11. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?
    Albright RH; Joseph RM; Wukich DK; Armstrong DG; Fleischer AE
    Clin Orthop Relat Res; 2020 Dec; 478(12):2869-2888. PubMed ID: 32694315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China.
    Deng W; Hu J; Li M; Yang S; Xie Z; Chen J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Oct; 22(7):1117-1126. PubMed ID: 35899310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
    Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
    Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of School Urinary Screening for Early Detection of IgA Nephropathy in Japan.
    Honda K; Akune Y; Goto R
    JAMA Netw Open; 2024 Feb; 7(2):e2356412. PubMed ID: 38363568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.